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Abstract
Background: Stiff Person Syndrome (SPS) is a rare autoimmune movement disorder characterized by the presence
of autoantibodies specific to the smaller isoform of glutamate decarboxylase (GAD65). A pathological role of these
antibodies has been suggested by their capacity to inhibit GAD65 enzyme activity and by the observation that rats
receiving cerebellar injections of GAD65Ab showed cerebellar motor hyperexcitability. To assess the effect of
epitope-specific GAD65Ab on cognitive and motor functions, we conducted behavioral experiments in rats that
received cerebellar injections with two distinct monoclonal GAD65Ab (b96.11 and b78).
Methods: Rats received three injections of GAD65Ab b96.11 (5 or 7 μg), GAD65Ab b78 (5 or 7 μg), or saline at the
level of three cerebellar nuclei. Animals were submitted to neurological evaluation and Morris Water Maze (MWM)
test. Cellular internalization of GAD65Ab was analyzed by Flow Cytometry, Fluorescence and Bright Field
microscopy.
Results: Monoclonal GAD65Ab induced dose-dependent and epitope-specific effects on motor and cognitive
functions. Injections of the higher dose altered motor and spatial procedural behaviors, while the lower dose
induced only modest cerebellar motor symptoms and did not affect MWM performances. While b96.11 provoked
immediate severe effects, which rapidly decreased, b78 induced moderate but prolonged effects. Both GAD65Ab
were taken up by live cells in a dose-dependent manner.
Conclusions: Our findings support the hypothesis that epitope-specific GAD65Ab induce cerebellar dysfunction
impairing motor and procedural abilities. This is the first demonstration of a critical role of cerebellar nuclei GAD65
enzyme in procedural spatial functions.
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Introduction
Gamma-Aminobutyric acid (GABA) is the major inhibi-
tory neurotransmitter in the mammalian central nervous
system (CNS). Its synthesis from glutamate is catalyzed
by two isoforms of glutamate decarboxylase, namely
GAD67 and GAD65 [1]. Only GAD65 is recognized by
autoantibodies present in patients with Type 1 diabetes
(T1D) and autoimmune movement disorders, including
Stiff Person Syndrome (SPS) [2] and certain subtypes of
Cerebellar Ataxia (CA) [3-5]. GAD65Ab in these three
disorders show distinct differences in their tissue distri-
bution and epitope specificities [6]. GAD65Ab in T1D
patients are found only in the periphery, while the anti-
bodies are present both in the periphery and the CNS in
SPS and CA patients [4,7]. Moreover, only GAD65Ab
present in SPS patients inhibit GAD65 enzyme activity
[8]. This latter observation together with the finding that
SPS patients have reduced levels of GABA in cerebro-
spinal fluid and brain [9,10] has led to the hypothesis
that GAD65Ab may have a pathogenic role. Yet the
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intracellular location of GAD65 and the assumed imper-
meability of intact neurons appeared to prevent access
of GAD65Ab to their target. However, a recent study by
Hill et al. challenged this view when they demonstrated
that IgG can be directly internalized by Purkinje cells
providing access to intracellular antigens [11]. Indeed, it
was reported that GAD65Ab down-regulated GABA
synthesis in basket cell terminals and thereby reduced
GABA release on Purkinje cells, thus selectively sup-
pressing GABAergic neurotransmission [12,13]. We in-
vestigated the effect of GAD65Ab on neuronal activity
by injecting rat cerebella with IgG purified from
GAD65Ab-positive SPS and CA patients [14]. The anti-
bodies impaired N-methyl-D-aspartate (NMDA)-medi-
ated turnover of glutamate, enhanced spinal cord
excitability, and altered adaptation of motor cortex to re-
petitive peripheral stimulation [14]. We concluded that
GAD65Ab interfered with the regulation of brain neuro-
transmitters and thereby impaired neuronal activity. This
conclusion was recently confirmed in studies demon-
strating that purified IgG from a SPS patient with high
GAD65Ab titers induced motor dysfunction in rats [15].
Both SPS and CA are characterized by dysfunctional
GABAergic neurotransmission [3,13] but show distinct
disease-specific symptoms. CA patients show moderate
to severe gait ataxia with mild limb ataxia and nys-
tagmus, while SPS patients show progressive muscular
rigidity, predominantly of the trunk muscles, with
superimposed spasms [16]. To investigate whether
disease-specific GAD65Ab are involved in these clinical
distinct phenotypes, we utilized two monoclonal
GAD65Ab with well-characterized epitope specificities.
One of these antibodies inhibited GAD65 enzyme activ-
ity and shared an epitope recognized by GAD65Ab
present in SPS patients [17]. Our hypothesis that differ-
ent GAD65Ab induce distinct neurological effects was
verified when we injected rat cerebellar nuclei with
these monoclonal GAD65Ab.
Specifically, we found that the SPS-associated mono-
clonal GAD65Ab induced greater effects regarding
increased glutamate concentration, decreased cerebello-
cortical inhibition, and impaired corticomotor response
[18]. These results could explain the different neuro-
logical syndromes observed in GAD65Ab-positive
patients.
Based on these results, we now analyzed the effects of
intra-nuclear cerebellar injections with two monoclonal
GAD65Ab (b96.11 and b78) on postural and spatial be-
havior in rats. To assess GAD65Ab-induced cerebellar
impairment, we submitted treated rats to a detailed
neurological evaluation and analyzed their performance
in the Morris Water Maze (MWM) test. This testing is
widely used to study motor and cognitive function in the
evaluation of cerebellar dysfunction [19-23].
Methods
Monoclonal antibodies b96.11 and b78
Human monoclonal antibodies b96.11 and b78 specific
to GAD65 were derived from a patient with Auto-
immune Polyendocrine Syndrome Type 1 [24]. This pa-
tient was non-diabetic and showed no symptoms of SPS.
Monoclonal antibodies were isolated from supernatants
of the respective B cell lines. The protein concentration
was adjusted to 1 mg/ml. Both antibodies show binding
to human, mouse and rat GAD65 without any reactivity
to GAD67. The conformational epitope recognized by
b96.11 is also bound by GAD65Ab in ~80% of T1D pa-
tients [25] and only by 50% of SPS patients [17]. Re-
markably, approximately 30% of SPS patients also
present T1D. The conformational epitope recognized by
b78 is bound by GAD65Ab present in 10% of T1D pa-
tients and 70% of SPS patients [17]. Notably, only b78
inhibits the enzyme activity of GAD65 [17].
Experimental design
Adult male Wistar rats (N=5/group) were injected in the
three deep cerebellar nuclei with 5 or 7 μg of monoclo-
nal GAD65Ab b96.11 (Group names: 5-b96.11, 7-b96
.11), GAD65Ab b78 (Group names: 5-b78, 7-b78) or
with the respective volumes of saline (5 and 7 μl) (Group
names: 5-sham, 7-sham). The doses used are based on
previous experiments demonstrating an effect on cere-
bellar nuclei [14]. All animals were pair- or three-housed
and kept under standard conditions with food and water
ad libitum on a 12/12hrs dark/light cycle. The neuro-
logical evaluation and MWM testing started 20 hrs after
the injections and lasted four post-injection days.
Surgery
All rats were anesthetized with Zoletil 100 (Tiletamine
and Zolazepam: 50 mg/kg i.p.-Virbac s.r.l., Milan, Italy)
and Rompun (Xylazine: 10 mg/Kg i.p.- Bayer s.p.a.,
Milan, Italy). Three injections were performed at the
level of the three right cerebellar deep nuclei (stereotaxic
coordinates: fastigial: AP -11.6, ML -1, DV -6.2; inter-
posed: AP -11.3, ML -2.2, DV -6.1; dentate: AP -11.3,
ML -3.4, DV -6.1) [26] (Figure 1). Solutions were
injected in each nucleus at flow rates of 1 μl/min. The
needle was left in situ 5 min after each injection. The
animals were allowed to recover from anesthesia and
surgical stress for 20 hrs.
Neurological evaluation
The presence of postural symptoms, locomotor handi-
caps, and complex behavior deficits was assessed by
means of a behavioral rating scale [20] (see Additional
file 1). A score from 0 to 2 was assigned to each symp-
tom according to its degree of severity (0=absent;
1=slight; 2=marked). As 20 behaviors were taken into
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account, the total score ranged from 0 (complete ab-
sence of any deficits) to 40 (presence of all symptoms to
the highest degree). The behavioral scores were attrib-
uted by an expert investigator unaware of the individual
specimen’s group (b96.11, b78 or sham). Behavioral eval-
uations were repeated for four post-injection days.
Morris Water Maze (MWM)
To test mnesic and procedural spatial functions in the
presence of intra-cerebellarly injected GAD65Ab, we
submitted the animals to the MWM test apt to evaluate
mnesic (localizatory competencies) and procedural
(navigational strategies) performances in animals with
cerebellar alterations [19-23]. To evaluate short-lasting
GAD65Ab effects we chose an MWM protocol detailing
both early (first 48 h) and more delayed effects in ana-
logy with an MWM protocol previously used [21]. The
rats were placed in a circular white pool (diameter 140
cm) filled with 24°C water made opaque by the addition
of atoxic acrylic black color (Giotto, Italy). An escape
platform (diameter 10 cm) was placed in the middle of
one quadrant (NW, NE, SW, SE), 30 cm from the side
walls. It was either submerged 2 cm or raised 2 cm
above the water level. On day 1, each rat was submitted
to 10-trial Place 1 phase (hidden platform put in the SE
quadrant), followed by 1 trial with no platform in the
pool (Probe 1) and then by a 4-trial Cue phase (visible
platform in the NW quadrant). Four hours later, the ani-
mals performed a 10-trial Place 2 phase (hidden plat-
form in the NW quadrant) followed by Probe 2. On day
2 and 3, the animals performed 10-trial Place 3 (hidden
platform in the NE quadrant) and 10-trial Place 4 (hid-
den platform in the SW quadrant) followed by Probe 3
and Probe 4, respectively.
The rat was released into the water from randomly
varied starting points and allowed to search for the hid-
den or visible platform for a maximum of 120 sec. When
the rat reached the platform, it was allowed to remain
there for 30 sec. The inter-trial interval was 1 min. In
the Probe phases the platform was removed and rats
were allowed 60 sec to search for it. Navigational trajec-
tories were recorded by a video camera whose signal was
relayed to a monitor and to an image analyzer
(Ethovision, Noldus, Wageningen, The Netherlands).
The following MWM parameters were considered: es-
cape latency (in sec) to find the platform; total distance
(in cm) swum in the pool; peripheral distance, consid-
ered as percentage of total distance swum in a 20-cm
peripheral annulus; mean swimming velocity (in cm/
sec); percentage of time spent in the previously rewarded
(platform) quadrant (× = time in sec/60 sec × 100) dur-
ing the Probe phase; navigational strategies put into ac-
tion in reaching the platform. The navigational strategies
were classified in six main categories, regardless of
whether the platform was reached or not: Circling (C):
circular swimming with inversion of direction and coun-
terclockwise and clockwise turnings; Extended Searching
(ES): swimming around the pool in all quadrants, visit-
ing the same area more than once; Restricted Searching
(RS): swimming in some pool quadrants, not visiting
other areas; Loop Searching (LS): swimming around the
pool with compulsive counterclockwise or clockwise re-
stricted turnings; Indirect Finding (IF): reaching the plat-
form by swimming through a semicircular trajectory;
direct Finding (F): swimming towards the platform with-
out any foraging around the pool. Animals were not
trained in MWM prior to injections to avoid prior ac-
quisition of skills. Two researchers unaware of the indi-
vidual specimen’s group categorized the swimming
trajectories drawn by the image analyzer. They attributed
the dominant behavior in each trial to a specific cat-
egory. Categorization was considered reliable only when
their judgments were consistent.
Uptake of antibodies by AF5 cells
The AF5 cell line (a kind gift from Dr. William J. Freed,
NIH) is an immortalized rat CNS cell line, which differen-
tiates to a neuronal phenotype with GAD65 expression
Figure 1 Illustration of the three unilateral injections in the deep cerebellar nuclei of the right side. The microphotograph (A) shows the
three tracks (arrowheads) of the injections into the cerebellar nuclei. The schematic drawing (B) of the corresponding coronal section (AP level:
between - 11. 6 and -11.3 mm from bregma) shows the three cerebellar nuclei. F: Fastigial; I: Interposed; D: Dentate nucleus.
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when allowed to grow to full confluency [26-28]. The cells
were maintained under permissive conditions in a 5% CO2
incubator in Neurobasal Media (Gibco Life Technologies,
Gaithersburg, MD) containing B-27 supplement (Gibco
Life Technologies), 0.5 mM L-glutamine, 100 U/ml peni-
cillin and 100 μg/ml streptomycin.
Expression of intracellular GAD65 in AF5 cells was
established using monoclonal GAD65 specific antibody
N-GAD65mAb (mouse) [29]. AF5 cells (1x106) were
fixed with 4% paraformaldehyde in phosphate-buffered
saline (PBS) for 7–10 min and then permeabilized with
ethanol: acetic acid (95:5) for 1–2 min at 20°C. N-
GAD65mAb was applied to the cells for 1 hour at 4°C.
After washes, bound N-GAD65mAb was detected by
secondary Tetramethyl Rhodamine Isothiocyanate
(TRITC)- labeled anti-mouse antibody (AbD Serotec,
Raleigh, NC). Cells were washed twice and examined by
flow cytometry (FACScan; Becton Dickinson, San Jose,
CA).
Internalization of GAD65Ab analyzed by flow cytometry
Monoclonal GAD65Ab b96.11 and b78 were labeled with
Alexa Fluor 488 according to the manufacturer’s instruc-
tions (Invitrogen, Carlsbad, CA). AF5 cells (1×106/100 μl)
were incubated with b96.11-Alexa-488 or b78-Alexa-488
(both at 1.6 μM) for the indicated times at 37°C. After
washes, cells were analyzed by flow cytometry as above.
Internalization of GAD65Ab analyzed by fluorescence and
bright field microscopy
AF5 (1×106/100 μl) cells were incubated with b78-Alexa
-488, b96.11- Alexa-488, or HAA1-Alexa 647 (all at
1.6 μM) for 4 hours at 37°C. After the last wash step,
cells were stained with SYTOX-Orange (Invitrogen)
according to the manufacturer’s instructions. Cells were
placed on a 35-mm Petri dish with glass bottom (cover
glass No. 1.5, MatTek, MA, USA), covered with Slow
Fade Light mounting solution or buffer (Molecular
Probes, Eugene, OR) and immediately analyzed. Images
were obtained with objective PlanApoN 60×/1.42 NA,
oil (Olympus) with image size 1024×1024 pixels. Cells
were visualized in bright field fluorescence mode using
the appropriate filter (FITC for Ex/Em 490/525 nm
(Alexa 488), Cy5 for Ex/Em 645/705 (Alexa 647),
TRITC for Ex/Em 555/605 (SYTOX-Orange)) and im-
ages were processed by the SoftWorX program (Version
5.0.0, Applied Precision, WA, USA). Intensity scale of
the respective channel was adjusted manually in the
histogram of Scale Image dialog box to remove fluores-
cence background of control cells (AF5 cells incubated
without labeled antibody). The images reported in the
figures are representative of at least three experiments
that gave similar results.
Statistical analysis
Data were presented as mean ± SEM and were tested
for normality (Will-Shapiro’s test) and homoscedasticity
(Levene’s test). When data distribution was not normal,
as for neurological evaluation scores, we applied the
non-parametric Mann-Whitney U test to compare total,
postural and locomotor symptoms and complex behav-
iors. MWM data were analyzed using one-way ANOVAs
(group) or two-way ANOVAs for independent (group)
and repeated measures (strategies) followed by Tukey’s
test, when appropriate. To control for the alpha inflation
the proportion of type I errors among all rejected null
hypotheses the False Discovery Rate (FDR) was set to
0.05. The FDR was estimated through the procedure de-
scribed by Storey and Tibshirani [30]. The bootstrap
procedure was used to estimate the π0 parameter [31].
In our results, the 0.05 level of significance corres-
ponded to an FDR 0.03.
Results
Animals injected with 7 μg of GAD65Ab
Neurological evaluation
Twenty hours after injections, 7-b96.11 animals showed
more severely impaired motor behaviors compared to 7-
sham animals. However, the motor impairment de-
creased after the first day so that the 7-b96.11 rats no
longer differed from 7-sham animals (Figure 2A). In
contrast, the 7-b78 rats exhibited slight motor impair-
ment (as compared to 7-sham rats) lasting for the entire
evaluation period (Figure 2A). Both GAD65Ab-treated
groups exhibited motor symptoms resembling those of a
right cerebellar dysfunction. To further characterize
motor behavior, the behavioral rating scale was sub-
divided in postural symptoms, locomotor asymmetries
and complex behaviors. When analyzing the postural
symptoms alone, we found that 7-b96.11 rats were im-
paired on post-injection day 1, after which the symptoms
rapidly decreased (Figure 2B). The same pattern was ob-
served for locomotor symptoms, where the impairment
displayed by 7-b96.11 rats was more severe compared to
7-sham rats on post-injection day 1, after which the
symptoms disappeared (Figure 2C). As for complex be-
haviors, both GAD65Ab-treated groups showed an im-
pairment more severe than observed in the 7-sham
group. On post-injection day 4, only rats in the 7-b78
group were still impaired in comparison to 7-b96.11 and
7-sham groups (Figure 2D). Results with significance dif-
ferences established by the non-parametric Mann-
Whitney U test on motor assessment data are depicted
in Figure 2.
Morris Water Maze
During Place 1 (20 h after injections), latency and per-
ipheral distance values were similar among groups, while
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total distances swum by 7-b96.11 animals were longer
than those of 7-sham rats. No differences were observed
between 7-b78 and 7-sham groups (Figure 3A-B). Swim-
ming velocities differed significantly among groups, with
7-b78 animals being significantly faster (= 27.82 ± 2.71
cm/sec) than 7-sham rats ( = 22.12 ± 0.57 cm/sec)
(p<0.03). No significant difference between 7-b96.11
(7-b96.11: = 25.86 ± 1.69 cm/sec) and 7-sham animals
was found. The analysis of the navigational strategies
revealed that 7-b96.11 rats exhibited the highest per-
centage of Circling (Figure 3C).
During the Cue phase, 7-b96.11 rats displayed higher la-
tency and total distance values in comparison to 7-sham
rats, while no difference was observed between 7-b78 and
7-sham rats (Figure 3A-B). No difference in swimming
velocity was found among groups. As for navigational
strategies, 7-b96.11 animals still exhibited the highest per-
centage of Circling (Figure 3C). The high latency and dis-
tance values of 7-b96.11 animals may be in part caused by
their enhanced Circling. During Place 2, Place 3 and Place
4, latency values, total and peripheral distances and navi-
gational strategies were not statistically different among
groups (Figure 3A-B).
In all Probe phases, no difference in the time spent in the
previously rewarded quadrant was observed among groups,
indicating no mnesic deficits induced by GAD65Ab. One-
way and two-way ANOVAs on MWM values are reported
(Additional file 2: Table S2 and Additional file 3: Table S3),
and relative post-hoc comparisons are depicted in Figure 3.
Animals injected with 5 μg of GAD65Ab
Neurological evaluation
Twenty hours after the injections, 5-b96.11 animals
exhibited total symptoms more severe than those ob-
served in 5-sham animals. From the second post-
injection day onward, no significant differences between
groups were detected. No significant difference was
found between 5-b78 and 5-sham rats at any time-point.
Results with significant differences as established by the
non-parametric Mann-Whitney U test on motor assess-
ment are depicted in Additional file 4: Figure S1.
Morris Water Maze
No difference among groups was evident for any of the
MWM parameters. One-way and two-way ANOVAs on
MWM values are reported (Additional file 2: Table S2
and Additional file 3: Table S3).
The main effects of the two epitope-specific GAD65Ab
on the various behavioral parameters are summarized in
Table 1.
Uptake of monoclonal GAD65Ab by AF5 cells
Expression of intracellular GAD65 in confluent AF5
cells was confirmed by flow cytometry and immunohis-
tochemistry (data not shown) employing the GAD65-
specific monoclonal antibody N-GAD65mAb. This
antibody shows no cross-reactivity with GAD67 [29].
Internalization of GAD65Ab by AF5 cells was tested
using Alexa-488-labeled b78 and b96.11 and analyzed
Figure 2 Neurological evaluation of total symptoms (A), postural symptoms (B), locomotor asymmetries (C) and complex behaviors
(D) in 7-b96.11 (black squares), 7-b78 (grey triangles), and 7-sham (white diamonds) groups. (7-b96.11 vs. 7-sham: * p <0.03;
7-b78 vs. 7-sham: # p <0.03; 7-b96.11vs. 7-b78: + p <0.03).
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by flow cytometry (Figure 4A). We observed that both
antibodies were internalized in a dose-dependent man-
ner. Uptake increased with time, reaching a plateau at
4 hours (data not shown). No uptake was observed at
4°C (data not shown), suggesting that the antibodies
were internalized and not surface-bound. This was fur-
ther confirmed by Fluorescence and Bright Field mi-
croscopy, demonstrating intracellular localization of
b78 and b96.11 (Figure 4B). Similar findings were ob-
served for human monoclonal antibody HAA1 against
Blood group A antigen. Staining with SYTOX-Orange
showed that antibodies were taken up by live cells. The
cellular distribution of labeled antibodies and SYTOX-
Orange clearly shows staining of nuclei with SYTOX-
Orange and staining of significantly smaller intracellu-
lar structures by the antibodies. Whether these small
intracellular structures are in fact vesicles remains to
be determined. The mechanism involved in the anti-
body uptake is currently under investigation.
Discussion
Intra-cerebellar injections of GAD65Ab affected both
motor and cognitive behaviors in an epitope-specific
manner. These effects were dose-dependent, given that
injections of 5 μg of GAD65Ab induced only mild and
transient cerebellar motor symptoms and did not affect
MWM performances (Table 1).
Cerebellar dysfunction elicits motor disorders in
muscle coordination, balance and muscle strength as
well as significant impairment in a variety of cognitive,
emotional, and affective functions [32-34]. Previously,
we demonstrated that the cerebellum plays a key role in
the acquisition of navigational procedural components
that control how a new environment is explored
[19,35,36]. In MWM, to acquire spatial information
hemicerebellectomized rats displayed ineffective ex-
plorative strategies, but show unaltered spatial mnesic
competencies.
The unilateral (right) intra-cerebellar injections of
GAD65Ab evoked postural and procedural effects similar
to those induced by a unilateral (right) cerebellar lesion
described in clinical [37,38] and experimental reports
[19,20,39], although the two monoclonal GAD65Ab
induced symptoms different in severity and duration.
Namely, b96.11-treated animals showed an initial severe
and rapidly decreasing impairment in motor symptoms
as well as in navigational strategies (Circling) and b78-
treated animals exhibited less severe but long-lasting
Figure 3 Comparisons among 7-b96.11 (black columns), 7-b78 (grey columns), and 7-sham (white columns) groups throughout MWM
testing. Escape latency (A), Total distance (B) and Navigational strategies (C) were depicted. The different navigational strategies are depicted
under the graphs. C: Circling; ES: Extended Searching; RS: Restricted Searching; LS: Loop Searching; IF: Indirect Finding; F: Finding.
(* p <0.03; ** p< 0.001).
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Table 1 Summary of main effects of epitope-specific GAD65Ab on behavioral parameters measured in this study
Neurological evaluation Morris water maze
Total symptoms Postural symptoms Locomotor asymmetries Complex behaviours Escape latency Total distance Navigational strategies
7-b96.11 Impairment (day1; p<0.03) Impairment
(day1; p<0.03)
Impairment
(day1; p<0.03)
Impairment
(day1, 3; p<0.03)
Increase
(Cue; p<0.03)
Increase
(Place1, Cue; p<0.03)
Circling Increase
(Place1, Cue; p<0.001)
5-b96.11 Impairment (day1; p<0.03) No Effect No Effect No Effect No Effect No Effect No Effect
7-b78 Impairment (day1, 3, 4; p<0.03) No Effect No Effect Impairment (day1, 3, 4; p<0.03) No Effect No Effect No Effect
5-b78 No Effect No Effect No Effect No Effect No Effect No Effect No Effect
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complex motor impairment. Notably, the intra-cerebellar
injections of either GAD65Ab did not affect motivational
components by modifying the salience of reward (plat-
form) and explorative tendencies. Neither were anxiety
levels affected by the GAD65Ab injections, as all groups
showed similar levels of peripheral swimming. Recently,
it has been described that rats injected multiple times
with polyclonal IgG purified from an SPS patient with
high GAD65Ab titers exhibited motor symptoms in-
creasing over time [15]. This result fits with the motor
deficits we observed in GAD65Ab-treated rats even fol-
lowing a single injection.
To advance a possible mechanism through which
GAD65Ab perturbed motor behaviors and navigational
competencies, several experimental findings have to be
taken into account. In cell and tissue culture systems,
IgG from GAD65Ab-positive neurological patients
suppressed GABA release from basket cells to Purkinje
cells [12,13], changing the balance between glutamate
and GABA and possibly causing glutamate excitotoxicity
[14,18]. Uptake of antibodies by neurons including
Purkinje cells has been recently demonstrated [11] and
we confirmed antibody uptake by the AF5 rat mesen-
cephalic cell line. Our recent in vivo studies support the
cellular uptake of GAD65Ab as b78 injected in the CA3-
CA1 area was detected in hippocampal interneurons
[40]. Future studies are planned to investigate the cellu-
lar localization of monoclonal GAD65Ab injected in the
cerebellar nuclei. Previously, we have shown that intra-
cerebellar injections of either b78 or b96.11 GAD65Ab
increased glutamate cerebellar levels, decreased cerebello-
cortical inhibition, and impaired cortico-motor response.
Interestingly, these effects were more severe if b78 was
injected [18]. Also in the present study b78 appears to
trigger longer-lasting effects as compared to b96.11. Based
on the observation that only b78 and not b96.11 inhibits
the enzyme activity of GAD65, we hypothesize that b78
reduces GABAergic transmission by inhibiting the enzyme
activity of GAD65. Alternatively, the GAD65Ab may inter-
fere with the exocytosis of GABA-containing vesicles
[14,18]. It is possible that a b96.11-mediated interference
with the exocytosis of GABA-containing vesicles will
eventually be overcome by increased GABA synthesis,
while the longer-lasting effects are the consequence of re-
duced GABA production mediated by b78. As suggested
by in vitro experiments, the pathogenic action of
GAD65Ab might consist of two phases: an early reversible
functional synaptic disorder and a subsequent irreversible
excitotoxic degeneration [41,42]. The observation that the
effectiveness of immunosuppressant agents on GAD65Ab-
Figure 4 Uptake of monoclonal GAD65Ab by the rat mesencephalic cell line AF5. Dose dependent uptake of monoclonal GAD65Ab b78
was assessed by flow cytometry (A). AF5 cells were incubated for 4 hours with 10 (blue line) and 50 μg (green line) Alexa-488 b78. Unstained
cells are shown in red. Cellular localization of GAD65Ab b78 and b96.11, and monoclonal antibody HAA1-Alexa 647 was assessed by fluorescence
and Bright Field microscopy (B). AF5 cells were incubated for 4 hours with Alexa-488 b78, Alexa-488 b96.11 or HAA1-Alexa 647 followed by
incubation with SYTOX-orange for identification of dead cells. The images reported in the figures are representative of at least three experiments
that gave similar results.
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positive CA patients depends on the clinical stage or the
degree of the disease supports this biphasic action model
[43,44]. Whether cerebellar injections with GAD65Ab in-
duce neuronal injury in rats remains to be determined.
A speculative possibility is that GAD65Ab impair the
nitric oxide (NO) pathway, which is critical for synaptic
plasticity in the cerebellum [45,46] and which is closely
related to the activation of NMDA receptors [47,48].
Alterations of biochemical mechanisms underlying cere-
bellar synaptic plasticity might be involved in the effects
reported here [49-51]. A GAD65Ab-mediated alteration
of the NO pathway would trigger neurotoxic processes
leading to altered behavioral outcome.
Conclusions
The present findings support the hypothesis that
disease-specific GAD65Ab induce distinct levels of im-
pairment in cerebellar circuits leading to motor and pro-
cedural symptoms different in severity and duration.
Cerebellar nuclei impairment would impact not only the
extra-cerebellar targets of cerebello-fugal pathways, but
also intrinsic cerebellar nuclear-cortical loops. In conclu-
sion, our study may represent a starting point in the ana-
lysis of behavioral effects of epitope specific GAD65Ab in
an attempt to characterize neurological syndromes associ-
ated with GAD65Ab and aid in the research for more
targeted antibody-mediated treatment strategies.
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